Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin N Rome

Showing results (31-40 of 139) with videos related to

Pageof 14
Sort By:
JAMA|October 4, 2022
Recent Trends in Prescription Drug Launch Prices-ReplyBenjamin N Rome, Alexander C Egilman, Aaron S Kesselheim
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 21, 2022
Medicaid Spending on Antiretrovirals From 2007 Through 2019Bryan S Walsh, Aaron S Kesselheim, Benjamin N Rome
JAMA Internal Medicine|May 17, 2021
Market Exclusivity and Changes in Competition and Prices Associated With the US Food and Drug Administration Unapproved Drug InitiativeSimon J Gunter, Aaron S Kesselheim, Benjamin N Rome
JAMA|June 7, 2022
Trends in Prescription Drug Launch Prices, 2008-2021Benjamin N Rome, Alexander C Egilman, Aaron S Kesselheim
Current Cardiology Reports|April 25, 2014
Approval of high-risk medical devices in the US: implications for clinical cardiologyBenjamin N Rome, Daniel B Kramer, Aaron S Kesselheim
Health Services Research|February 23, 2023
Market dynamics of authorized generics in Medicaid from 2014 to 2020Benjamin N Rome, Simon J Gunter, Aaron S Kesselheim
Health Services Research|July 14, 2025
Share of Sales Subject to Medicare Inflation Rebates and Price Increases of Top-Selling DrugsAlexander C Egilman, Aaron S Kesselheim, Benjamin N Rome
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|May 31, 2024
Medicare Should Cover Weight Loss Drugs as Long as the Prices are AffordableCatherine S Hwang, Aaron S Kesselheim, Benjamin N Rome
JAMA Internal Medicine|September 8, 2020
US Spending Associated With Transition From Daily to 3-Times-Weekly Glatiramer AcetateBenjamin N Rome, Frazer A Tessema, Aaron S Kesselheim
JAMA Internal Medicine|January 18, 2022
Medicaid Spending on Drugs Marketed Without US Food and Drug Administration Approval in 2020Simon J Gunter, Aaron S Kesselheim, Benjamin N Rome
Pageof 14

Showing results (31-40 of 139) with videos related to

Sort By:
Pageof 14
JAMA|October 4, 2022
Recent Trends in Prescription Drug Launch Prices-ReplyBenjamin N Rome, Alexander C Egilman, Aaron S Kesselheim
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 21, 2022
Medicaid Spending on Antiretrovirals From 2007 Through 2019Bryan S Walsh, Aaron S Kesselheim, Benjamin N Rome
JAMA Internal Medicine|May 17, 2021
Market Exclusivity and Changes in Competition and Prices Associated With the US Food and Drug Administration Unapproved Drug InitiativeSimon J Gunter, Aaron S Kesselheim, Benjamin N Rome
JAMA|June 7, 2022
Trends in Prescription Drug Launch Prices, 2008-2021Benjamin N Rome, Alexander C Egilman, Aaron S Kesselheim
Current Cardiology Reports|April 25, 2014
Approval of high-risk medical devices in the US: implications for clinical cardiologyBenjamin N Rome, Daniel B Kramer, Aaron S Kesselheim
Health Services Research|February 23, 2023
Market dynamics of authorized generics in Medicaid from 2014 to 2020Benjamin N Rome, Simon J Gunter, Aaron S Kesselheim
Health Services Research|July 14, 2025
Share of Sales Subject to Medicare Inflation Rebates and Price Increases of Top-Selling DrugsAlexander C Egilman, Aaron S Kesselheim, Benjamin N Rome
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|May 31, 2024
Medicare Should Cover Weight Loss Drugs as Long as the Prices are AffordableCatherine S Hwang, Aaron S Kesselheim, Benjamin N Rome
JAMA Internal Medicine|September 8, 2020
US Spending Associated With Transition From Daily to 3-Times-Weekly Glatiramer AcetateBenjamin N Rome, Frazer A Tessema, Aaron S Kesselheim
JAMA Internal Medicine|January 18, 2022
Medicaid Spending on Drugs Marketed Without US Food and Drug Administration Approval in 2020Simon J Gunter, Aaron S Kesselheim, Benjamin N Rome
Pageof 14